Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 17, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Axitinib (AG-013736).

Ronan Joseph Kelly1, Olivier Rixe

  • 1Thoracic Oncology Department Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA. kellyro@mail.nih.gov

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|January 15, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors.

Cancer·2025
Same author

Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan.

The oncologist·2025
Same author

A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.

Journal for immunotherapy of cancer·2023
Same author

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022
Same author

Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2021
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, shows promise in treating various cancers by blocking tumor angiogenesis. Further phase III studies will define its therapeutic role.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Tumor angiogenesis, driven by vascular endothelial growth factor (VEGF)/VEGF receptor tyrosine kinase (RTK) signaling, is crucial for tumor growth and metastasis.
  • Antiangiogenic agents, including multi-RTK inhibitors, are vital in cancer therapy.
  • Axitinib selectively inhibits VEGF RTK 1, 2, and 3.

Purpose of the Study:

  • To discuss the structure, toxicities, and drug interactions of axitinib.
  • To present preclinical and clinical data for axitinib in various tumor types.

Main Methods:

  • Review of preclinical data.
  • Analysis of phase II clinical trial findings in multiple cancer types.
  • Discussion of ongoing phase III studies.

Main Results:

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Experiment Videos

Last Updated: Jun 17, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

  • Axitinib demonstrates activity in preclinical models and phase II trials across several malignancies.
  • Ongoing phase III trials are evaluating axitinib in pancreatic and metastatic renal cell carcinoma.

Conclusions:

  • Axitinib is a potent VEGF RTK inhibitor with potential therapeutic applications in oncology.
  • Further research, particularly phase III trials, is necessary to establish the definitive role of axitinib in cancer treatment.